Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2018

01-07-2018 | Head and Neck Oncology

The Impact of Metronomic Adjuvant Chemotherapy in Patients with Advanced Oral Cancer

Authors: Ming-Yu Hsieh, MD, Gene Chen, Dun-Cheng Chang, PhD, Su-Yu Chien, RPh, MS, Mu-Kuan Chen, MD, MSc, PhD

Published in: Annals of Surgical Oncology | Issue 7/2018

Login to get access

Abstract

Background

This study evaluated the efficacy of tegafur-uracil for advanced oral cancer.

Methods

From January 2008 to December 2013, clinical data from 356 patients with stage III or IV oral squamous cell carcinoma who received curative surgical resection and postoperative concurrent chemoradiotherapy, treated with or without tegafur-uracil, were analyzed from a prospectively designed database. Tegafur-uracil was orally administered to 114 of the 356 patients. Disease-specific survival (DSS), disease-free survival (DFS), and overall survival (OS) rates were studied.

Results

In our study, the 5-year OS (p = 0.0008), DFS (p = 0.0034), and DSS (p = 0.0029) rates were significantly better in the tegafur-uracil group than in the control group. Distant metastasis occurred in 16.28% of patients in the tegafur-uracil group and 45.28% in the control group (odds ratio 4.3). The distant metastasis rate in the tegafur-uracil group was significantly lower than the control group, indicating that administration of tegafur-uracil after curative surgical treatment and concurrent chemoradiotherapy prevented distant metastasis and improved the OS, DFS, and DSS rate.

Conclusions

The result of tegafur-uracil treatment in patients with advanced oral cancer showed significant improvement in the 5-year OS, DFS, and DSS rate, while also showing a decreased distant metastasis rate. Tegafur-uracil treatment is a useful, effective, and well-tolerated anticancer treatment for advanced oral cancer.
Literature
1.
2.
3.
4.
Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23(22):4999–5006.CrossRefPubMed
5.
Lo WL, Kao SY, Chi LY, et al. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg. 2003;61(7):751–8.CrossRefPubMed
6.
Tsukahara K, Kubota A, Hasegawa Y, et al. Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). PLoS ONE. 2015;10(2):e0116965.CrossRefPubMedPubMedCentral
7.
Hu JM, Chou YC, Wu CC, et al. Adjuvant chemotherapy with tegafur/uracil for more than 1 year improves disease-free survival for low-risk Stage II colon cancer. J Chin Med Assoc. 2016;79(9):477–88.CrossRefPubMed
8.
Tanaka J, Inuyama Y, Fujii M, et al. Clinical trials on UFT in the treatment of head and neck cancer. Auris Nasus Larynx. 1985;12(Suppl 2):S261–6.CrossRefPubMed
9.
Takahashi H, Yao K, Sawaki S, et al. Investigation of UFT and radiation combination therapy of head and neck cancer–mainly in laryngeal cancer. Gan To Kagaku Ryoho. 1990;17:2037–42.PubMed
10.
Tsukuda M, Miyake H. Maintenance chemotherapy with UFT for head and neck carcinoma. Oncology 2000;14(Suppl 9):93–5.
11.
Shiba R, Kawamata R, Rahman OIF, et al. Prophylaxis of tumour recurrence and metastasis with a mixture of tegafur and uracil in head and neck cancers. Asian J Oral Maxillofac Surg. 2003;15(1):38–43.CrossRef
12.
Twu CW, Wang WY, Chen CC, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys. 2014;89(1):21–9.CrossRefPubMed
13.
Wang HM, Hsu CL, Hsieh CH, et al. Concurrent chemoradiotherapy using cisplatin, tegafur, and leucovorin for advanced squamous cell carcinoma of the hypopharynx and oropharynx. Biomed J 2014;37(3):133–40.PubMed
14.
Segura Huerta A, Díaz-Beveridge R, Pérez-Fidalgo JA, et al. Carboplatin and tegafur-uracil concomitant with standard radiotherapy in the management of locally advanced head and neck cancer. Clin Transl Oncol. 2005; 7(1):23-8.CrossRefPubMed
15.
Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12(11):2248–53.CrossRefPubMed
16.
Nakanishi H, Kobayashi K, Nishimura T, et al. Chemosensitivity of micrometastases and circulating tumor cells to uracil and tegafur as evaluated using LacZ gene-tagged Lewis lung carcinoma cell. Cancer Lett. 1999;142(1):31–41.CrossRefPubMed
17.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.CrossRefPubMed
18.
Bonner J, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.CrossRefPubMed
19.
20.
Metadata
Title
The Impact of Metronomic Adjuvant Chemotherapy in Patients with Advanced Oral Cancer
Authors
Ming-Yu Hsieh, MD
Gene Chen
Dun-Cheng Chang, PhD
Su-Yu Chien, RPh, MS
Mu-Kuan Chen, MD, MSc, PhD
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6497-3

Other articles of this Issue 7/2018

Annals of Surgical Oncology 7/2018 Go to the issue

Colorectal Cancer

High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal

Gastrointestinal Oncology

Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer

Gastrointestinal Oncology

Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved

Breast Oncology

Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?

Health Services Research and Global Oncology

Changing the Status Quo, Including How We Measure It

Bone and Soft Tissue Sarcomas

Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World